Lamivudine

Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI) . Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].

Product Specifications

CAS Number

[134678-17-4]

Product Name Alternative

BCH-189

UNSPSC

12352005

Hazard Statement

H361

Target

HBV; HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Lamivudine.html

Concentration

10mM

Purity

99.99

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

OC[C@H]1SC[C@@H](N2C(N=C(N)C=C2)=O)O1

Molecular Formula

C8H11N3O3S

Molecular Weight

229.26

Precautions

H361

References & Citations

[1]Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26 (1) :216-25. |[2]Olaniyan LW, et al. Lamivudine-Induced Liver Injury. Open Access Maced J Med Sci. 2015 Dec 15;3 (4) :545-50. |[3]Mdanda S, et al. Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder. Assay Drug Dev Technol. 2019 Oct;17 (7) :322-329.